ES3001108T3 - Moléculas quiméricas y usos de las mismas - Google Patents

Moléculas quiméricas y usos de las mismas Download PDF

Info

Publication number
ES3001108T3
ES3001108T3 ES18775234T ES18775234T ES3001108T3 ES 3001108 T3 ES3001108 T3 ES 3001108T3 ES 18775234 T ES18775234 T ES 18775234T ES 18775234 T ES18775234 T ES 18775234T ES 3001108 T3 ES3001108 T3 ES 3001108T3
Authority
ES
Spain
Prior art keywords
ectodomain
fusion protein
polypeptide
chimeric polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18775234T
Other languages
English (en)
Spanish (es)
Inventor
Keith Chappell
Daniel Watterson
Paul Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63675061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3001108(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2017901152A external-priority patent/AU2017901152A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Application granted granted Critical
Publication of ES3001108T3 publication Critical patent/ES3001108T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES18775234T 2017-03-30 2018-03-29 Moléculas quiméricas y usos de las mismas Active ES3001108T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017901152A AU2017901152A0 (en) 2017-03-30 Chimeric molecules and uses thereof
PCT/AU2018/050299 WO2018176103A1 (en) 2017-03-30 2018-03-29 "chimeric molecules and uses thereof"

Publications (1)

Publication Number Publication Date
ES3001108T3 true ES3001108T3 (es) 2025-03-04

Family

ID=63675061

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18775234T Active ES3001108T3 (es) 2017-03-30 2018-03-29 Moléculas quiméricas y usos de las mismas

Country Status (15)

Country Link
US (2) US11254712B2 (enExample)
EP (2) EP3601367B1 (enExample)
JP (2) JP7291398B2 (enExample)
KR (1) KR20190135017A (enExample)
CN (1) CN110506060B (enExample)
AU (1) AU2018241252B2 (enExample)
BR (1) BR112019019813A2 (enExample)
CA (1) CA3057171A1 (enExample)
DK (1) DK3601367T3 (enExample)
ES (1) ES3001108T3 (enExample)
IL (1) IL269534B2 (enExample)
MX (1) MX2019011599A (enExample)
PL (1) PL3601367T3 (enExample)
SG (1) SG11201908280SA (enExample)
WO (1) WO2018176103A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079796A1 (en) * 2007-12-24 2009-07-02 Id Biomedical Corporation Of Quebec Recombinant rsv antigens
SI3178490T1 (sl) 2009-07-15 2022-08-31 Glaxosmithkline Biologicals S.A. Sestavki proteina F RSV-ja in postopki za pripravo le-teh
SI3275892T1 (sl) 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
CA3110842A1 (en) 2018-02-15 2019-08-22 Caretech Services Pty Ltd A platform and system for use in therapeutic procedures
WO2020085457A1 (ja) * 2018-10-25 2020-04-30 Ｋｍバイオロジクス株式会社 改変ＣＭＶ ｇＢタンパク質及びこれを含むＣＭＶワクチン
EP3999107A1 (en) * 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
EP4004018A1 (en) * 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
EP4086275A4 (en) * 2019-12-31 2024-04-17 Xiamen University Multimerization delivery system for intracellular delivery of molecule
WO2021155733A1 (zh) * 2020-02-05 2021-08-12 复旦大学 多肽、其制备方法和用途
JP2023513135A (ja) * 2020-02-06 2023-03-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 抗ラブドウイルス抗体を検出するのに有用なポリペプチド
CN112300251B (zh) * 2020-02-24 2022-04-05 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白及疫苗
WO2021216560A2 (en) * 2020-04-20 2021-10-28 Richard Ascione Vaccine compositions for sars-related coronaviruses and methods of use
MX2022013934A (es) * 2020-05-07 2023-02-22 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.
MX2022015489A (es) * 2020-06-10 2023-03-22 Bavarian Nordic As Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
US20230256090A1 (en) 2020-06-29 2023-08-17 Glaxosmithkline Biologicals Sa Adjuvants
EP4192500A4 (en) * 2020-08-10 2025-01-01 The Scripps Research Institute COMPOSITIONS AND METHODS RELATED TO EBOLAVIRUS VACCINES
US20240033343A1 (en) * 2020-08-26 2024-02-01 The University Of Queensland Modified polypeptides with improved properties
US11175293B1 (en) * 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using
US20240285755A1 (en) 2021-05-24 2024-08-29 Glaxosmithkline Biologicals Sa Adjuvants
US20240317810A1 (en) * 2021-07-15 2024-09-26 Board Of Regents, The University Of Texas System Prefusion-stabilized chimeric hmpv-rsv f proteins
US20230096087A1 (en) * 2021-09-24 2023-03-30 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie Prefusion-stabilized herpesvirus glycoprotein-b
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
KR20250011901A (ko) * 2022-03-31 2025-01-22 더 유니버서티 어브 퀸슬랜드 개선된 키메라 폴리펩타이드 및 이의 용도
WO2023196945A2 (en) * 2022-04-08 2023-10-12 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof
AU2023339047A1 (en) 2022-09-09 2025-03-20 Repligen Corporation Affinity agents
CN116789847B (zh) * 2023-01-13 2024-04-16 广州医科大学附属第一医院（广州呼吸中心） 融合蛋白、病毒样颗粒以及疫苗
WO2024186980A2 (en) * 2023-03-08 2024-09-12 Dana-Farber Cancer Institute, Inc. Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof
CN119978144B (zh) * 2025-02-14 2025-10-17 嘉译生物医药(杭州)有限公司 一种hMPV病毒融合蛋白F变体、mRNA疫苗及其应用
CN119841911B (zh) * 2025-03-18 2025-10-28 北京华诺泰生物医药科技有限公司 一种人偏肺病毒f蛋白突变体及其应用
CN120248083B (zh) * 2025-06-05 2025-09-30 腾讯科技（深圳）有限公司 Glp-1r和gcgr双靶点激活多肽或其衍生物、药学上可接受的盐及它们的用途

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5849572A (en) 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
WO1992019266A1 (en) 1991-05-06 1992-11-12 The United States Of America, As Represented By The Department Of Health And Human Services Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6361770B1 (en) 1994-09-23 2002-03-26 University Of British Columbia Method of enhancing expression of MHC class I molecules bearing endogenous peptides
JP3907698B2 (ja) 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
DE19650370A1 (de) 1996-12-05 1998-06-10 Basf Ag Flammwidrige thermoplastische Formmassen auf der Basis von Polyarylenethern
US5849561A (en) 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US6893866B1 (en) 1997-11-28 2005-05-17 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
DK2272859T3 (en) 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2003530073A (ja) * 1999-07-09 2003-10-14 アメリカ合衆国 弱毒化されたヒト−ウシキメラ呼吸器合胞体ウィルスワクチンの製造
DE60039766D1 (de) 1999-08-09 2008-09-18 Targeted Genetics Corp Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
ES2256265T3 (es) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados.
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
CA2448066A1 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
US7569383B2 (en) 2001-06-01 2009-08-04 Acambis Inc. Chimeric flavivirus vectors
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
DK1412493T3 (da) 2001-08-02 2012-01-09 Inst Clayton De La Rech Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer
DE60233061D1 (de) 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
RU2305708C2 (ru) 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
AU2002352913B2 (en) 2001-11-30 2008-05-29 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptide agonists of prostate-specific antigen, and uses therefor
ES2602352T3 (es) 2001-12-17 2017-02-20 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 8 de virus adenoasociado (VAA), vectores que las contienen y usos de las mismas
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
RS53476B (sr) 2003-07-18 2014-12-31 Amgen Fremont Inc. Sredstva za specifično vezivanje faktora rasta hepatocita
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
EP1858332A4 (en) 2005-02-16 2011-06-22 Lentigen Corp LENTIVIRUS VECTORS AND ITS USE
KR20080052512A (ko) 2005-05-23 2008-06-11 박신, 인크. 아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20090304641A1 (en) 2005-10-17 2009-12-10 Children's Hospital Boston Methods and Compositions for Regulating Gene Expression
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
US20070249043A1 (en) 2005-12-12 2007-10-25 Mayall Timothy P Adenoviral expression vectors
US20100184832A1 (en) 2006-07-14 2010-07-22 Sanofi Pasteur Biologics Co. Construction of Recombinant Virus Vaccines by Direct Transposon-Mediated Insertion of Foreign Immunologic Determinants into Vector Virus Proteins
CA2676719A1 (en) 2007-02-09 2008-08-21 Sanofi Pasteur Biologics Co. Viral vectors and methods of use
WO2009019612A2 (en) 2007-08-03 2009-02-12 Institut Pasteur Lentiviral gene transfer vectors and their medicinal applications
US8815564B2 (en) 2008-03-14 2014-08-26 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
US8871515B2 (en) 2008-09-17 2014-10-28 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
JP2012510806A (ja) 2008-12-08 2012-05-17 コンプリクス エン ヴェー 単鎖逆平行コイルドコイルタンパク質
PL3067064T3 (pl) * 2008-12-09 2020-11-02 Novavax, Inc. Zmodyfikowane białka f rsv i sposoby ich wykorzystania
CA2755257A1 (en) 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
WO2010114948A2 (en) 2009-04-02 2010-10-07 University Of Florida Research Foundation, Inc. An inducible system for highly efficient production of recombinant adeno-associated virus (raav) vectors
SI3178490T1 (sl) 2009-07-15 2022-08-31 Glaxosmithkline Biologicals S.A. Sestavki proteina F RSV-ja in postopki za pripravo le-teh
CA2781519A1 (en) * 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011043719A1 (en) 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US20120294889A1 (en) 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines
CA2827375C (en) 2011-02-14 2022-07-19 The Children's Hospital Of Philadelphia Improved aav8 vector with enhanced functional activity and methods of use thereof
WO2012145509A2 (en) 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors, and viruses
SI3275892T1 (sl) * 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
US9506041B2 (en) 2012-03-26 2016-11-29 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Delivery of packaged RNA to mammalian cells
SI2839014T1 (sl) 2012-04-18 2021-05-31 The Children's Hospital Of Philadelphia Sestavek in postopki za zelo učinkovit prenos genov z uporabo variant kapside AAV-JA
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
JP2015529466A (ja) 2012-09-14 2015-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター
SG10201702292YA (en) 2012-09-21 2017-05-30 Agency Science Tech & Res Novel attenuated dengue virus strains for vaccine application
BR112015011389A2 (pt) 2012-11-20 2017-08-22 Glaxosmithkline Biologicals Sa Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US20140271708A1 (en) 2013-03-15 2014-09-18 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies G
CA2919773A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
CA3033105A1 (en) 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
KR20250011901A (ko) 2022-03-31 2025-01-22 더 유니버서티 어브 퀸슬랜드 개선된 키메라 폴리펩타이드 및 이의 용도

Also Published As

Publication number Publication date
IL269534B1 (en) 2024-09-01
DK3601367T3 (da) 2025-01-13
JP2023071901A (ja) 2023-05-23
AU2018241252B2 (en) 2024-09-19
US12116386B2 (en) 2024-10-15
US20220127309A1 (en) 2022-04-28
US20200040042A1 (en) 2020-02-06
JP2020515272A (ja) 2020-05-28
EP4512820A2 (en) 2025-02-26
US11254712B2 (en) 2022-02-22
PL3601367T3 (pl) 2025-03-31
BR112019019813A2 (pt) 2020-04-22
EP3601367A4 (en) 2020-09-16
SG11201908280SA (en) 2019-10-30
EP3601367B1 (en) 2024-10-09
WO2018176103A1 (en) 2018-10-04
EP3601367A1 (en) 2020-02-05
IL269534B2 (en) 2025-01-01
CN110506060B (zh) 2024-05-07
KR20190135017A (ko) 2019-12-05
CN110506060A (zh) 2019-11-26
JP7291398B2 (ja) 2023-06-15
IL269534A (en) 2019-11-28
AU2018241252A1 (en) 2019-10-03
EP4512820A3 (en) 2025-05-21
MX2019011599A (es) 2019-12-19
CA3057171A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
ES3001108T3 (es) Moléculas quiméricas y usos de las mismas
US20240226012A1 (en) Novel multivalent nanoparticle-based vaccines
US20230023093A1 (en) Dna antibody constructs and method of using same
Ellis et al. Stabilization of the SARS-CoV-2 spike receptor-binding domain using deep mutational scanning and structure-based design
BE1023087B1 (fr) Antigenes du cytomegalovirus et leurs utilisations
KR20210021530A (ko) 신규한 구조적 컴포넌트들을 갖는 나노입자 백신들
JP2019115355A (ja) Ｄｎａ抗体構築物およびその使用方法
CN112512567A (zh) 抗原性呼吸道合胞病毒多肽
WO2021262672A1 (en) Sars-cov-2 rbd constructs
CN114989308A (zh) 新冠病毒嵌合核酸疫苗及其用途
JP2023540486A (ja) 免疫原性コロナウイルス融合タンパク質および関連方法
EP4204000A1 (en) Modified polypeptides with improved properties
US20250223319A1 (en) Improved chimeric polypeptides and uses thereof
CN116847882A (zh) Hiv疫苗及其使用方法
CN116964104A (zh) 免疫原性冠状病毒融合蛋白及相关方法
Tantral Impact of ebola mucin-like domain on anti-glycoprotein antibodies induced by ebola virus-like particles